Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Why should benign mastopathies be treated medically?].

P Mauvais-Jarvis

    Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Not Available].

    International journal of cosmetic science·2009
    Same author

    Long-term follow-up of 246 hyperprolactinemic patients.

    Acta obstetricia et gynecologica Scandinavica·2001
    Same author

    Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease.

    Cancer detection and prevention·1999
    Same author

    Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia.

    Journal of endocrinological investigation·1999
    Same author

    Predominant expression of 5 alpha-reductase type 1 in pubic skin from normal subjects and hirsute patients.

    The Journal of clinical endocrinology and metabolism·1996
    Same author

    [Guidelines from the National Federation of Cancer Prevention Centers (FNCLOC) on trials of drug prevention of breast cancer by tamoxifen ].

    Bulletin du cancer·1995
    Same journal

    [Neuroprotection for preterm infants with antenatal magnesium sulphate].

    Journal de gynecologie, obstetrique et biologie de la reproduction·2017
    Same journal

    [Is universal screening for cervical length among singleton pregnancies with no history of preterm birth justified?]

    Journal de gynecologie, obstetrique et biologie de la reproduction·2017
    Same journal

    [Lifestyle recommendations for prevention of spontaneous preterm birth in asymptomatic pregnant women].

    Journal de gynecologie, obstetrique et biologie de la reproduction·2017
    Same journal

    [Guidelines for clinical practice: Prevention of spontaneous preterm birth (excluding preterm premature rupture of membranes) - Introduction].

    Journal de gynecologie, obstetrique et biologie de la reproduction·2017
    Same journal

    [Psychological aspects of abortion].

    Journal de gynecologie, obstetrique et biologie de la reproduction·2016
    Same journal

    [Induced abortion: Guidelines for clinical practice - Introduction].

    Journal de gynecologie, obstetrique et biologie de la reproduction·2016
    See all related articles

    This study reviews therapeutic options for benign breast diseases, emphasizing the need for precise pathological diagnosis to evaluate hormone treatments like progestogens, Danazol, and Bromocriptine effectiveness.

    Area of Science:

    • Gynecology
    • Oncology
    • Pathology

    Context:

    • Benign breast diseases (BBDs) encompass a range of conditions requiring accurate diagnosis and treatment.
    • Therapeutic strategies for BBDs are evolving with increased understanding of disease pathophysiology.
    • Hormone therapies, including progestogens, Danazol, and Bromocriptine, are common treatment modalities.

    Purpose:

    • To analyze various therapeutic approaches for benign breast diseases.
    • To evaluate the efficacy of hormone treatments based on specific pathological abnormalities.
    • To determine if BBD treatments can mitigate high-risk cellular abnormalities and potentially prevent breast cancer.

    Summary:

    • The paper examines therapeutic options for benign breast diseases, highlighting the critical role of precise pathological evaluation.

    Related Experiment Videos

  • Objective assessment of hormone treatments (progestogens, Danazol, Bromocriptine) requires understanding specific pathological features.
  • Investigates the potential of these treatments to modify high-risk cellular changes, such as lobular hyperplasia, and their role in breast cancer prevention.

    • Impact:

    • Informs clinical decision-making for benign breast disease management.
    • Guides research towards more targeted and effective therapeutic strategies.
    • Contributes to understanding the link between benign breast conditions and breast cancer risk reduction.